CD Skripsi
Sintesis Dan Molecular Docking Senyawa Pirazolin (E)-7-(3-Bromobenziliden)-3(3-Bromofenil)-3,3a,4,5,6,7-Heksahidro-2h-Pirazolo[4,3-C]Piridin-2-Karbotioamida Sebagai Kandidat Antidiabetes
Pyrazolin is a dihydropyrazole derivative which is an azole group compound with
a 5-heterocyclic structure containing 2 nitrogen. Pyrazoline is known to have
several bioactivities and antidiabetic is an activity that is provided by pyrazoline.
Pyrazoline (E)-7-(3-bromobenzyliden) -3- (3-bromophenyl) -3,3a,4,5,6,7-
hexahydro-2H-pyrazolo [4,3-c]pyridine-2- Carbotioamides are synthesized from
bromo-substituted curcumin and thiosemicarbazide through the Claisen-Schmidt
condensation reaction. The structure of the synthesized compound was confirmed
by characterization using UV, FTIR, 1H-NMR and HRMS spectroscopy. Pyrazoline
was tested for their antidiabetic activity through molecular docking and in vitro
studies. Molecular docking studies were carried out on the crystal structure of
human lysosomal α-glucosidase (PDB ID: 5NN5) and compared with acarbose as
a positive control. The activity of the pyrazoline PL-3Br-PN is classified as weak
in inhibiting the α-glucosidase enzyme, which is 10.876%. This result was
confirmed by molecular docking studies that it only has one hydrogen bond
interaction in common with acarbose, namely the amino acid His674. The bond free
energy of PL-3Br-PN obtained a higher value, which is -15,5423 kcal/mol
compared to acarbose, which is -21,3876 kcal/mol. Based on the results obtained,
it can be concluded that PL-3Br-PN is less effective as an antidiabetic candidate.
Tidak tersedia versi lain